Seeking Alpha On July 10, 2013, Omni Bio Pharmaceutical , Inc. (OMBP.OB) announced it will be collaborating with the University of Michigan Cancer Center (UMCC) and Leukemia and Lymphoma Society (LLS) to study plasma-derived alpha-1 antitrypsin (p-AAT) for the ...
MENAFN.COM Jul 18, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --Biopharmaceutical company Omni Bio Pharmaceutical Inc OMBP reported on Wednesday the election of Sandra J. Wrobel MBA to its board of directors, with effect from 15 July 2013. Currently, Wrobel ...
PharmExec.com Are you aware of all of the opportunities for manufacturers available through strategic utilization of the retail channel? Do you know about the partnerships being formed and innovative programs being launched at the pharmacy? Last fall, more than 100 ...
Marketwire (press release) DENVER, CO--(Marketwired - Jul 17, 2013) - Omni Bio Pharmaceutical , Inc. ("Omni Bio") ( OTCBB : OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of ... and more »
4-traders (press release) alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced its financial support for a clinical trial of AAT for the treatment of complications following bone marrow ...
